Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150981 · ClinicalTrials.gov registry record · Phase 2
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
A Phase 2 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01150981 is a Phase 2 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 35 participants.
The verdict
NCT01150981, a Phase 2 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.
Interventions
- DRUG Placebo
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150981
The ClinicalTrials.gov registry entry for NCT01150981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01150981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150981 about?
NCT01150981 is a clinical study titled "Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue". Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing b...
What is the current status of trial NCT01150981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2006-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01150981?
The interventions under investigation include: Placebo (DRUG), Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT01150981?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.